Oral Communications

RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED ESSENCE TRIAL OF THE TOPICAL INVESTIGATIONAL DRUG SD-101 IN PATIENTSWITHEPIDERMOLYSIS BULLOSA: OVERALL RESULTS AND KEY SUBGROUP ANALYSES C. Kowalewski, M. Nikolic, D. Murrell, J. Browning, A. Paller, C. Bodemer, H. Ott, D. Kiritsi, A. Reha, J. Barth, H. Lagast Medical University of Warsaw, Warsaw, Poland, Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia, University of New South Wales, Sydney, Australia, Texas Dermatology and Laser Specialists, San Antonio, USA, Northwestern University Feinberg School of Medicine, Chicago, USA, The University Hospital Necker Enfants Malades, Paris, France, Children’s Hospital Auf der Bult, Hanover, Germany, Medical Center-University of Freiburg, Freiburg, Germany and Amicus Therapeutics, Inc., Cranbury, USA